25 research outputs found
Biochemical mutagens affect the preservation of fungi and biodiversity estimations
Many fungi have significant industrial applications
or biosafety concerns and maintaining the original
characteristics is essential. The preserved fungi have to
represent the situation in nature for posterity, biodiversity
estimations, and taxonomic research. However, spontaneous
fungal mutations and secondary metabolites affecting
producing fungi are well known. There is increasing
interest in the preservation of microbes in Biological
Resource Centers (BRC) to ensure that the organisms
remain viable and stable genetically. It would be anathema
if they contacted mutagens routinely. However, for
the purpose of this discussion, there are three potential
sources of biochemical mutagens when obtaining individual
fungi from the environment: (a) mixtures of microorganisms
are plated routinely onto growth media
containing mutagenic antibiotics to control overgrowth
by contaminants, (b) the microbial mixtures may contain
microorganisms capable of producing mutagenic secondary
metabolites, and (c) target fungi for isolation may
produce “self” mutagens in pure culture. The probability
that these compounds could interact with fungi undermines
confidence in the preservation process and the
potential effects of these biochemical mutagens are considered
for the first time on strains held in BRC in this
review
The highly accurate anteriolateral portal for injecting the knee
<p>Abstract</p> <p>Background</p> <p>The extended knee lateral midpatellar portal for intraarticular injection of the knee is accurate but is not practical for all patients. We hypothesized that a modified anteriolateral portal where the synovial membrane of the medial femoral condyle is the target would be highly accurate and effective for intraarticular injection of the knee.</p> <p>Methods</p> <p>83 subjects with non-effusive osteoarthritis of the knee were randomized to intraarticular injection using the modified anteriolateral bent knee versus the standard lateral midpatellar portal. After hydrodissection of the synovial membrane with lidocaine using a mechanical syringe (reciprocating procedure device), 80 mg of triamcinolone acetonide were injected into the knee with a 2.0-in (5.1-cm) 21-gauge needle. Baseline pain, procedural pain, and pain at outcome (2 weeks and 6 months) were determined with the 10 cm Visual Analogue Pain Score (VAS). The accuracy of needle placement was determined by sonographic imaging.</p> <p>Results</p> <p>The lateral midpatellar and anteriolateral portals resulted in equivalent clinical outcomes including procedural pain (VAS midpatellar: 4.6 ± 3.1 cm; anteriolateral: 4.8 ± 3.2 cm; p = 0.77), pain at outcome (VAS midpatellar: 2.6 ± 2.8 cm; anteriolateral: 1.7 ± 2.3 cm; p = 0.11), responders (midpatellar: 45%; anteriolateral: 56%; p = 0.33), duration of therapeutic effect (midpatellar: 3.9 ± 2.4 months; anteriolateral: 4.1 ± 2.2 months; p = 0.69), and time to next procedure (midpatellar: 7.3 ± 3.3 months; anteriolateral: 7.7 ± 3.7 months; p = 0.71). The anteriolateral portal was 97% accurate by real-time ultrasound imaging.</p> <p>Conclusion</p> <p>The modified anteriolateral bent knee portal is an effective, accurate, and equivalent alternative to the standard lateral midpatellar portal for intraarticular injection of the knee.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00651625">NCT00651625</a></p